A microfluidics platform for combinatorial drug screening on cancer biopsies

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Eduati, Federica ^a,b,g   Utharala, Ramesh ^b   Madhavan, Dharanija ^b   Neumann, Ulf Peter ^c,d,e   Longerich, Thomas ^c,h   Cramer, Thorsten ^c,d,e   Saez Rodriguez, Julio ^a,f,i   Merten, Christoph A ^b  

^a EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RWTH AACHEN UNIVERSITY   (Germany)

^g EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ACHP; ANTINEOPLASTIC AGENT; CASPASE 3; GEFITINIB; GEMCITABINE; I KAPPA B KINASE INHIBITOR; MOMELOTINIB; OXALIPLATIN; PHT 427; PICTILISIB; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; SELUMETINIB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

CANCER; CELL; DETECTION METHOD; DISEASE TREATMENT; DRUG; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPC-1 CELL LINE; BXPC-3 CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HEALTH CARE COST; MICROFLUIDICS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; TUMOR BIOPSY; ANIMAL; BIOPSY; DEVICES; ECONOMICS; FEMALE; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; NEOPLASM; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; TUMOR CELL LINE; VALIDATION STUDY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MICROFLUIDICS; NEOPLASMS; PRECISION MEDICINE;

EID: 85048985572     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-04919-w     Document Type: Article

References (46)

1. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
2. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
3. Witkiewicz, A. K. et al. Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. Cell Rep. 16, 2017-2031 (2016).
4. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
5. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
6. Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740-754 (2016).
7. Costello, J. C. et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat. Biotechnol. 32, 1202-1212 (2014).
8. Eduati, F. et al. Prediction of human population responses to toxic compounds by a collaborative competition. Nat. Biotechnol. 33, 933-940 (2015).
9. Friedman, A. A., Letai, A., Fisher, D. E. &Flaherty, K. T. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15, 747-756 (2015).
10. Al-Lazikani, B., Banerji, U. &Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
11. Griner, L. A. M. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large Bcell lymphoma cells. Proc. Natl Acad. Sci. USA 111, 2349-2354 (2014).
12. Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977-989 (2015).
13. Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 3, 1416-1429 (2013).
14. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933-945 (2015).
15. Huang, L. et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell-and patient-derived tumor organoids. Nat. Med. 21, 1364-1371 (2015).
16. Ruppen, J. et al. Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab. Chip. 15, 3076-3085 (2015).
17. Astolfi, M. et al. Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. Lab. Chip. 16, 312-325 (2016).
18. Ma, W.-Y. et al. A novel 96well-formatted micro-gap plate enabling drug response profiling on primary tumour samples. Sci. Rep. 5, 9656 (2015).
19. Shembekar, N., Chaipan, C., Utharala, R. &Merten, C. A. Droplet-based microfluidics in drug discovery, transcriptomics and high-throughput molecular genetics. Lab. Chip. 16, 1314-1331 (2016).
20. Wong, A. H.-H. et al. Drug screening of cancer cell lines and human primary tumors using droplet microfluidics. Sci. Rep. 7, 9109 (2017).
21. Gruner, P. et al. Controlling molecular transport in minimal emulsions. Nat. Commun. 7, 10392 (2016).
22. Gu, W., Zhu, X., Futai, N., Cho, B. S. &Takayama, S. Computerized microfluidic cell culture using elastomeric channels and Braille displays. Proc. Natl Acad. Sci. USA 101, 15861-15866 (2004).
23. Zec, H., Rane, T. D. &Wang, T.-H. Microfluidic platform for on-demand generation of spatially indexed combinatorial droplets. Lab. Chip. 12, 3055-3062 (2012).
24. Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
25. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495-501 (2015).
26. Clausell-Tormos, J. et al. Droplet-based microfluidic platforms for the encapsulation and screening of Mammalian cells and multicellular organisms. Chem. Biol. 15, 427-437 (2008).
27. Clausell-Tormos, J., Griffiths, A. D. &Merten, C. A. An automated two-phase microfluidic system for kinetic analyses and the screening of compound libraries. Lab. Chip. 10, 1302-1307 (2010).
28. Tung, Y.-C., Torisawa, Y.-S., Futai, N. &Takayama, S. Small volume low mechanical stress cytometry using computer-controlled Braille display microfluidics. Lab. Chip. 7, 1497-1503 (2007).
29. Chen, D. L., Li, L., Reyes, S., Adamson, D. N. &Ismagilov, R. F. Using threephase flow of immiscible liquids to prevent coalescence of droplets in microfluidic channels: criteria to identify the third liquid and validation with protein crystallization. Langmuir 23, 2255-2260 (2007).
30. Zhou, J., Ellis, A. V. &Voelcker, N. H. Recent developments in PDMS surface modification for microfluidic devices. Electrophoresis 31, 2-16 (2010).
31. Abu-Qare, A. W. &Abou-Donia, M. B. Biomarkers of apoptosis: release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2'-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J. Toxicol. Environ. Health B Crit. Rev. 4, 313-332 (2001).
32. Deer, E. L. et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39, 425-435 (2010).
33. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4, 437-450 (2003).
34. Kelley, R. K. &Ko, A. H. Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2, 83 (2008).
35. Eser, S., Schnieke, A., Schneider, G. &Saur, D. Oncogenic KRAS signalling in pancreatic cancer. Br. J. Cancer 111, 817-822 (2014).
36. Hu, C. et al. Combined inhibition of cyclin-dependent kinases (Dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models. Mol. Cancer Ther. 14, 1532-1539 (2015).
37. Meuillet, E. J. et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Cancer Ther. 9, 706-717 (2010).
38. Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B. &Sorger, P. K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
39. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
40. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
41. El Debs, B., Utharala, R., Balyasnikova, I. V., Griffiths, A. D. &Merten, C. A. Functional single-cell hybridoma screening using droplet-based microfluidics. Proc. Natl Acad. Sci. USA 109, 11570-11575 (2012).
42. Gonzalez, R., Lee, J. W. &Schultz, P. G. Stepwise chemically induced cardiomyocyte specification of human embryonic stem cells. Angew. Chem. Int. Ed. 50, 11181-11185 (2011).
43. Wu, X., Ding, S., Ding, Q., Gray, N. S. &Schultz, P. G. Small molecules that induce cardiomyogenesis in embryonic stem cells. J. Am. Chem. Soc. 126, 1590-1591 (2004).
44. Theberge, A. B. et al. Microfluidic platform for combinatorial synthesis in picolitre droplets. Lab. Chip. 12, 1320-1326 (2012).
45. Miller, O. J. et al. High-resolution dose-response screening using dropletbased microfluidics. Proc. Natl Acad. Sci. USA 109, 378-383 (2012).
46. Eduati, F. et al. Data and code for "A microfluidics platform for combinatorial drug screening on cancer biopsies". Zenodo. https://doi.org/10.5281/ zenodo.1248886 (2018).